Racial Differences: Nitric Oxide(NO) and Endothelin-1(ET-1) in Preeclampsia (PreE)

Preeclampsia Clinical Trial

Official title:

Elucidating the Role of Nitric Oxide and Endothelin-1 Activation in Endothelial Cells Co-cultured With Placental Explants From African-american and Caucasian High Risk Pregnancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00653809
• Other study ID #: 2007-0065
• Status: Completed
• Phase: N/A
• First received: April 1, 2008
• Last updated: April 5, 2012
• Start date: June 2007
• Est. completion date: September 2009

Study information

• Verified date: April 2012
• Source: University of Mississippi Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The goal of this study is to examine the activation of markers of endothelial and cardiovascular dysfunctions, from women with high-risk pregnancies. Information from this study will hopefully provide enough information to determine a link between race, the advent of high risk pregnancies and cardiovascular markers. With this information it might be possible to intervene with approved pharmacological treatments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: September 2009
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• African-american or Caucasian

• Pregnant

• Between ages of 18 - 40 years of age

Exclusion Criteria:

• Presence of a disease or condition which is not preeclampsia

• Drug or alcohol abuse during pregnancy

• Obesity

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Pre-Eclampsia
• Preeclampsia

Locations

Country	Name	City	State
United States	University of MS Medical Center	Jackson	Mississippi

Sponsors (3)

Lead Sponsor	Collaborator
University of Mississippi Medical Center	Mississippi Institute for Improvement of Geographic Minority Health, Office of Minority Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Nitric oxide and Endothelin-1 levels		48 hours after tissue collection	No
Secondary	Nitric oxide isoforms and Endothelin-1 receptor activation based on primary outcome		within 6 months from tissue collection	No